5-Amino-4-(diazoacetyl)-1-beta-D-ribofuranosylimidazole, a new antileukemic agent.
5-Amino-4-(diazoacetyl)-1-beta-D-ribofuranosylimidazole (15), 5-amino-4-(chloroacetyl)-1-beta-D-ribofuranosylimidazole (16), and a number of related imidazole ribonucleosides have been synthesized. Compounds 15 and 16 are cytotoxic to both H.Ep.-2 and L1210 leukemia cells in culture. The (diazoacetyl)imidazole 15 is also active against the P388 leukemia in mice.
D000620:Aminoimidazole Carboxamide / Q000031:analogs & derivatives / Q000138:chemical synthesis* / Q000633:toxicity; D000818:Animals; D000970:Antineoplastic Agents / Q000138:chemical synthesis*; D006528:Carcinoma, Hepatocellular / Q000473:pathology; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D006801:Humans; D007093:Imidazoles / Q000138:chemical synthesis*; D007202:Indicators and Reagents; D007939:Leukemia L1210 / Q000473:pathology; D008113:Liver Neoplasms / Q000473:pathology; D009682:Magnetic Resonance Spectroscopy; D013058:Mass Spectrometry; D051379:Mice; D012263:Ribonucleosides / Q000138:chemical synthesis* / Q000633:toxicity; D013329:Structure-Activity Relationship
D000970:Antineoplastic Agents; D007093:Imidazoles; D007202:Indicators and Reagents; D012263:Ribonucleosides; C050958:5-amino-4-(diazoacetyl)-1-ribofuranosylimidazole; D000620:Aminoimidazole Carboxamide